Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: A randomized, controlled trial

Retina

Volumn 29, Issue 9, 2009, Pages 1218-1226

  Lai, Timothy Y Y ^a,b   Liu, David T L ^a,c   Chan, Kwok Ping ^a   Luk, Fiona O J ^a,b   Pang, Chi Pui ^a   Lam, Dennis S C ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG EYE HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Dosage; Pigment epithelial derived factor; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; GROWTH FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN;

ADULT; AGED; ANGIOGRAPHY; AQUEOUS HUMOR; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; RETINITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VISION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; EYE PROTEINS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MALE; NERVE GROWTH FACTORS; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 70350139329     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b32c45     Document Type: Article

References (28)

1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137:486-495.
2. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007;114:253-262.
3. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
4. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1432-1444.
5. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
6. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
7. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-390. (Pubitemid 44197628)
8. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
9. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
10. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-1641.
11. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007;27:432-438.
12. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 2008;146:91-95.
13. Krebs I, Lie S, Stolba U, Zeiler F, Felke S, Binder S. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol 2008 Oct 17 [Epub ahead of print].
14. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444.
15. Arevalo JF, Fromow-Guerra J, Sanche JG, et al; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in agerelated macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008;28:1387-1394.
16. Rosenfeld PJ. Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol 2006;142:141-143.
17. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epitheliumderived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141: 456-462.
18. Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelialderived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008;28: 1308-1313.
19. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349: 427-434.
20. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide Br J Ophthalmol 2006;90:1344-1349.
21. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26:257-261.
22. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
23. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-274.
24. Heiduschka P, Julien S, Hofmeister S, Bartz-Schmidt KU, Schraermeyer S. Bevacizumab (Avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina 2008;28:46-55.
25. Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina 2009;29:319-324.
26. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One 2008;3:e3554.
27. Roh MI, Kim HS, Song JH, Lim JB, Koh HJ, Kwon OW. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with AMD after bevacizumab treatment. Retina 2009;29: 523-529.
28. Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. Retina 2005; 25:691-696.